NCT06820749View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

April 23, 2026

Study Completion Date

June 22, 2026

Conditions
Asthma BronchialeBronchiectasisChronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

HSK31858

HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 12-week treatment period in patients with airway mucus hypersecretion in chronic airway inflammatory diseases

DRUG

Placebo

the placebo comparator of study

Trial Locations (1)

100020

Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing

All Listed Sponsors
lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY